A simple guide to the interpretation of the significance of the association of a disease with a particular HLA allele

Winchester Robert
Division of Rheumatology, Columbia University, New York, NY, USA

Summary
This review is a simple guide to the deeper meaning of the association of a disease with a particular HLA allele. We will first review some principles of the function of the adaptive immune system, and some basic notions of autoimmune disease. In this, we will focus on the tripartite unity of the human leukocyte antigen (HLA) molecule, the peptide, and the T cell receptor that recognizes the complex of peptide and HLA molecule, placing emphasis on the function of the T cell receptor. We will also touch on the evolutionary forces shaping our adaptive immune system. Then we will apply this background to some current HLA data concerning the heterogeneity of psoriatic arthritis and the extent to which it is relayed to psoriasis, to illustrate how these principles are used to advance our understanding of the disease.

Keywords: HLA association, autoimmune disease, human leukocyte antigen (HLA), peptide T cell receptor (TCR), psoriasis, psoriatic arthritis

Introduction
Finding that a disease is associated with a human leukocyte antigen (HLA) allele tells us, firstly, with a few exceptions, that underlying the disease is a T cell driven adaptive immune response to specific peptides. This adaptive immune response is directed either against an infectious pathogen, i.e. non-self, or is autoinimmune in nature, and its more specific nature may well have therapeutic implications. Secondly, at the clinical level, because many complex diseases are diagnosed or classified by syndromic clinical criteria, the presence of a strong HLA association provides an important additional diagnostic criterion, and may also reveal unexpected insight into disease heterogeneity. This review is a simple guide to the deeper meaning of the association of a disease with a particular HLA allele. In it we will use the term “HLA” in this guide rather than the equivalent, but more general term “major histocompatibility complex” (MHC).

Each individual’s immune system is nearly unique because the T cells are selected on self-peptides contained in self-HLA molecules

Selection of the individual’s T cell repertoire on self-peptides presented by self-HLA molecules
T cell clones comprising the adaptive immune system function by specifically recognizing virtually every pathogen protein by one or more of its constituent peptides. The challenge of the immense diversity of pathogen peptides results in a series of biologic processes that distinguish the adaptive immune system from all other systems in the body. The first of these biologic processes is that to generate the trillions of different T cell clones that are specific for different peptides requires random somatic generation through DNA recombinatorial mechanisms of the T cell peptide clonal receptors (TCR) that distinguish each clone. This, because there is insufficient room in the germ line genome to encode each of the billions of different TCRs as individual genes. The second is that since the peptide recognized are generally nine amino acids in length they require a protein structure to bind these different short peptide ligands in a specific manner to ensure their appropriate recognition by the TCR. This is the role of the HLA molecule. Amongst the universe of peptides to which T cells in general could respond, the particular peptides that the T cells of any individual can perceive are specified by the particular binding properties of that person’s HLA molecules. Typically, two amino acid side chains of the peptide fit into pockets in the HLA molecule, tightly anchoring to form a peptide-HLA complex (fig. 1). The peptide-HLA complex is specifically recognized by the T cell TCR through specific contact sites on the peptide and on the HLA molecule. The third, and perhaps the most critical for understanding autoimmune disease, is that since all the T cell clones comprising the repertoire are developed prior to encountering the pathogen, self-peptides are used as the surrogate for the pathogen peptide. These self-peptides bound to self-HLA molecules serve as examples or prototypes of all the possible pathogen peptides that the immune system will encounter and select the individual’s T cell clones that will comprise their T cell repertoire to be used in future immune responses against some of these
pathogens. The fourth is that the process of random TCR generation necessitates a selection process that positively selects potentially useful clones for that individual with TCR that effectively recognize self-peptides bound to self-HLA molecules. Additionally, this process includes several mechanisms that eliminate or inactivate clones with overly strong reactivity to self-peptides presented by self-HLA molecules.

Accordingly, the T cell repertoires of the adaptive immune system that are selected on self-peptides bound to self-HLA molecules are, at the level of the recognition event of the peptide-HLA molecule, incapable of distinguishing between an HLA molecule bearing a self-peptide or a pathogen peptide. The T cell, distinguished by a TCR that is likely incapable of distinguishing between self- or pathogen-peptide, is then guided by a variety of accessory and co-stimulatory molecules to specifically react to pathogen peptides, and in turn to the pathogen. This is accomplished by the microenvironment established in lymphoid tissues in large part determined by dendritic and other antigen-presenting cells that initially encountered the pathogen and its constituent peptides in a peripheral site. These T cells that initiate the immune response were initially selected, perhaps years earlier, in the thymus by self-peptide analogues of the pathogen peptide.

Since all T cell clones are selected on self-peptides, the development of autoimmunity and an autoimmune disease is increasingly being viewed as an untoward consequence of the inappropriate triggering of these previously quiescent T cell clones that were selected on self-peptides. This is in contrast to the earlier concept of a dichotomous state of “autoimmunity, in contrast to the “normal” T cell clones populated healthy individuals that are incapable of recognizing self.

However, in the instance of an autoimmune disease, the specificity of a particular activated T cell clone for self-peptides derived from a given protein defines that protein as the fundamental target tissue of the autoimmune response. The character of the autoimmune response is also determined on both the peptide, and on the HLA molecule.

Since each different type of HLA molecule selects its own repertoire of T cells according to the binding of a different set of peptides, the resulting diversity in T cell recognition properties constitutes an evolutionary advantage in dealing with a pathogen. To diversify the peptide-presenting structures in the individual evolutionary processes led to the three types of class I HLA molecules designated HLA-A, HLA-B, and HLA-C. These are encoded, respectively, at the three HLA-A, HLA-B and HLA-C loci. This single alpha chain encodes the entire peptide-binding domain of the molecule. Each of these three subtypes of HLA molecules selects their own repertoire of T cells. These T cells recognize different peptides in the context of the respective HLA class I molecule. Because the genes encoding these molecules are inherited from both parents and are co-dominantly expressed, we consequently have six sets of different
peptide-presenting class I HLA molecules that have each selected their own unique repertoire of T cells. Analogously, there are three types of class II HLA molecules designated HLA-DR, HLA-DQ, and HLA-DP, that similarly select distinct T cell repertoires. Although the overall conformation of the class II HLA molecule resembles that of the class I molecule, they consist of two chains, alpha (A) and beta (B), that are synthesized by separate loci in the class II region, and together form the peptide binding domain of the molecule. These chains are encoded by HLA-DRA, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 loci. Only the expressed polymorphic HLA loci are illustrated in the simplified figure 2. Also, not illustrated for reasons of space, are those essentially monomorphic HLA genes that have important immune functions, some additional polymorphic loci such as DRB3, etc., as well as a number of HLA pseudogenes that continue to play a dynamic genomic role. Some of these genetic terms used in figure 2 are defined in table 1. The reader is referred to references such as [1] for additional details about the HLA system.

Different varieties of HLA molecules within the species
Because a given variety of HLA molecule can only bind and present a certain repertoire of peptides limited by the specificity of its pockets to bond certain peptide amino acid side chains, the evolutionary response of the species to the diversity of pathogen proteins and peptides has driven the development of a very large number of alternative gene

Table 1: Nomenclature used to describe the genetic polymorphisms of HLA genes.

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alleles</td>
<td>the alternative forms of a gene found in different individuals (the gene name is usually italicized)</td>
</tr>
<tr>
<td>Allotypes or allomorphs</td>
<td>the different or alternative protein forms encoded by alleles</td>
</tr>
<tr>
<td>Genotype</td>
<td>the collection of genes in an individual, often referring to the two alleles of a single locus present on the respective maternal and paternal chromosomes</td>
</tr>
<tr>
<td>Haplotype</td>
<td>the genes (alleles) on a chromosome or region of the chromosome contributed by one parent. It is usually referred to by naming the principal alleles in the region. It can span across both class I and class II regions.</td>
</tr>
<tr>
<td>Gene loci exhibit linkage</td>
<td>a measure of their genetic distance</td>
</tr>
<tr>
<td>Linkage disequilibrium</td>
<td>certain alleles of different genes comprising a haplotype are found together significantly more (or less) frequently than expected by chance in certain populations and geographic regions. These stable haplotypes are referred to as conserved haplotypes.</td>
</tr>
</tbody>
</table>

Figure 2: The overall genetic organization of the HLA gene complex, located on the short arm of chromosome 6. This gene complex is approximately 4 million base pairs in length and the principal illustrated HLA loci are divided into two main functionally different classes, class I and class II. These classes reflect the two fundamentally different immunosurveillance challenges faced by the immune system: identification of an infected cell and an extracellular pathogen. There are three class I loci: HLA-A, HLA-B and HLA-C. The molecules encoded by each of these three loci selects their own repertoire of T cells that recognize different peptides in the context of the respective HLA class I molecule. There are three types of class II HLA molecules designated HLA-DR, HLA-DQ, and HLA-DP; however they consist of two chains, alpha (A) and beta (B), and are synthesized by separate loci. Only the expressed polymorphic HLA loci are illustrated in this simplified figure. The large number of alternative gene forms, or alleles, found at each of these loci is illustrated.
forms at each locus, termed “alleles”, which encode alternative molecules termed “allomorphs”. These allomorphs are distinguished by major differences in their preferences to bind different varieties of peptides, based on the nature of the amino acids forming the pockets in the HLA molecules that govern their preference for particular anchor amino acids, and consequently for different peptides. The number of alternative alleles for each of the loci illustrated in figure 2 that have been identified to date across all humankind is orders of magnitude greater than the number of alleles at any other site in the genome. This immense genetic diversity reflects the power of the evolutionary drive to make the recognition properties of the adaptive immune system of each individual different from those of another person. This strategy of diversifying the antigen-presenting characteristics of HLA molecules in each individual offers the species a powerful mechanism for surviving a virulent pandemic.

A large proportion of the HLA alleles are present in the population at a frequency significantly greater than could be accounted for by random mutation; that is, they are considered to be genetically polymorphic. The two most common mechanisms affecting the frequency of the various HLA alleles in different populations are:

1. Frequency-dependent selection: the individual with the rarest allele has the best chance to survive an infection in an epidemic.
2. Heterozygote advantage: the individual with more HLA structures can present more, different pathogen peptides.

Accordingly, there is no single HLA allomorph that is universally and intrinsically superior to any other in all circumstances. It is simply that in the context of a pathogen in a specific environment, one allele is more effective at binding peptides of that pathogen. This confers a survival advantage to that person for that pathogen and specific environment. However, even in this environment there is a contravening principle. Genetic pluralism in a population (the presence of a variety of different HLA alleles), rather than uniformity is evolutionarily advantageous because a new pathogen could mutate to accommodate to the recognition properties encoded by a too-preponderant allomorph. Accordingly, the HLA-B*27 allele, though associated with ankylosing spondylitis, has clearly been positively selected in some geographic regions. This is primarily influenced by the amino acids of the amino acids forming the pockets in the HLA molecule that surround the peptide binding groove. This accounts for the dual specificity of a T cell clone for both peptide specifically bound to the HLA molecule, and the surrounding regions of the polymorphic HLA molecule.

Conserved haplotypes

The last topic in HLA genetics to become familiar with is the concept of conserved “ancestral” haplotypes. A haplotype refers to the unit of haploid chromosomal inheritance containing the genes provided by the mother or the father. One might anticipate that any HLA-A allele would be found on a haplotype with any HLA-B allele, and this is generally true across all humankind, but because crossing over between loci in the HLA region is quite infrequent, different peoples originating from different geographic areas are strongly characterized by particular combinations of certain HLA-A and HLA-B alleles, a phenomenon called linkage disequilibrium. This largely reflects different pathogen selection mechanisms acting in different geographic regions, founder effects, as well as subsequent effects due to migration, etc. For example, among northern Europeans, the HLA-B*08:01 allele is nearly always found on the same 6th chromosome with the HLA-C*07:01 allele, constituting a conserved haplotype. Thus, in populations of northern European ancestry, an association of a disease phenotype with HLA-B*08:01 will also be manifest as an association with HLA-C*07:01. Linkage disequilibrium and the attendant formation of conserved haplotypes complicate the interpretation of HLA associations, but correspondingly are at the heart of the genetic architecture responsible for a given person’s adaptive immune system.

Autoimmune disease

Since the entire T cell system is selected on self-peptides and self-HLA, it is inherently autoreactive and if triggered, these T cells will be responsible for autoimmunity. In effect, autoimmune diseases are just another adaptive immune response, but with two major differences: They are...
directed to a self-peptide, not a pathogen peptide, and they evolve slowly, and often inexorably, over a number of years. The key to their understanding and therapy is to think of them as immune responses reflecting the individuality of each person’s immune system, and not as conceptually fixed disease entities.

One classification of autoimmune diseases is based on the class of HLA molecule implicated in susceptibility. For example, HLA Class I associated diseases include ankylosing spondylitis, psoriasis and psoriatic arthritis. Each of these diseases are characterized by the presence of clonally expanded CD8 T cells in lesional sites and the absence of autoantibodies, suggesting that the critical event underlying these diseases is presentation of a self-peptide by class I molecules to a CD8 T cell. In contrast, there is a large group of diseases whose occurrence is associated with the inheritance of a particular class II HLA allele, including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis and Type I diabetes mellitus. These class II HLA allele-associated diseases are characterized by CD4 T cells in lesional sites and usually characterized by autoantibodies, reflecting their differentiation to a stage where they are capable of providing specific help to a B cell.

This close association of susceptibility to different autoimmune diseases with different HLA alleles implies both that the autoimmune response is determined by the person’s HLA allotype reflecting the ability to bind a specific self-peptide, and that the protein/organ containing the peptide becomes the target of the autoimmune response. We emphasize the major role of the HLA alleles in disease susceptibility, but it is critical to understand that it is the distinctive recognition features of the T cell repertoire selected by the individual’s HLA allomorphs, and the specific identification of target antigens by the T cells comprising this repertoire that actually are responsible for the particular disease.

The natural history of each autoimmune disease or this asymptomatic autoimmunity this phase progresses in intensity with further T cell clonal expansion, spreading, and in some instances further B cell help, until the autoimmune response achieves a state where it begins to mediate tissue injury, denoting entrance into the third phase of a recognizable autoimmune disease.

**The psoriasis phenotype: psoriasis and psoriatic arthritis**

Psoriasis is a prototypic autoimmune disease that is among the most common of the autoimmune diseases. Figure 3 summarizes the main conclusion of extensive studies on the genetic basis of psoriasis, showing disease susceptibility maps into the HLA-C locus, and specifically with the HLA-C/*06:02 allele [2–4]. Three common psoriasis susceptibility ancestral haplotypes are illustrated in which the C/*06:02 allele is in linkage disequilibrium with either of the HLA-B loci alleles: B*13:01, B*37:01 or B*57:01. Several additional neighboring gene loci in the gene rich HLA region are also depicted that were earlier candidates for psoriasis susceptibility.
Based on prospective studies largely carried out in psoriasis cohorts, many textbooks describe psoriatic arthritis as developing in 15–20% of psoriasis patients after the passage of 10–15 years. With this as background, we set out to ask and more specifically, is the genotype of psoriatic arthritis identical to that of psoriasis? Does the phenotypic frequency of the HLA-C*06:02 allele in psoriatic arthritis parallel that found in psoriasis? We used DNA-based allele typing. The reader is referred to this [5] and other cited primary references for greater methodologic details. Briefly, the approach was to compare the HLA genotypes of two cohorts in the homogeneous Irish population with psoriasis that were meticulously characterized by Oliver FitzGerald and David Kane; University College Dublin using CASPAR criteria for inclusion. The psoriasis cohort (n = 214) was without features of arthritis, spondylitis or enthesitis and presented to a dermatology clinic, whereas the psoriatic arthritis cohort (n = 359) presented to a rheumatology clinic. Of the psoriasis cohort, 57.5% had the HLA-C*06:02 allele compared with 19.3% in a control population (odds ratio [OR] 6.61, p <0.0001), a value consistent with that reported in the dermatologic literature for the northern European population. This is depicted in figure 4. The frequency of HLA-C*06:02 in the psoriatic arthritis cohort was only 27.9%, significantly lower than that in the psoriasis cohort (OR 0.30, p <0.0001), but still significantly increased over that of the control population (OR 1.9, p <0.0001). This confirms that the HLA-C*06:02 allele is associated with psoriatic arthritis. There were two main implications of this study: The psoriasis phenotype is not genetically homogeneous (\( p = 9.94 \times 10^{-5} \)) [2], and psoriatic arthritis itself is heterogeneous, with only a smaller subset genetically closely related to those with cutaneous psoriasis [5].

The next question was, which HLA alleles are present in the balance of psoriatic arthritis patients who have not inherited C*06:02? These results are sketched in figure 4 and showed HLA-B*27:05:02 and HLA-B*39:01:01 and B*38:01:01 are indeed susceptibility alleles for psoriatic arthritis, as has been previously described, but are not high-risk alleles for psoriasis in the absence of musculoskeletal involvement. Moreover, HLA-B*08:01 contributes to psoriatic arthritis susceptibility, but interestingly, unlike HLA-B*27:05:02, B*39:01:01 and B*38:01:01 or C*06:02, the B*08:01 allele appears relatively “protective” for the development of psoriasis in the absence of arthritis. This result provides strong support for the conclusion that psoriatic arthritis is genetically heterogeneous and analogous results have been obtained by other groups [6].

This finding that psoriasis is genetically heterogeneous with the musculoskeletal-cutaneous phenotype of psoriatic arthritis defined by several HLA-B locus alleles and C*06:02 suggests that both HLA-B locus alleles and HLA-C locus alleles play a role in driving the psoriatic arthritis association, but with some differences in the resulting clinical phenotype, as will be discussed in a little more detail subsequently. The phenotype conferred by HLA-C*06:02 was identified as one of highly penetrant severe skin disease and lower penetrance musculoskeletal disease, whereas HLA-B*27:05:02, HLA-B*39:01:01 and HLA-B*08:01 confer equivalent penetrance for milder skin and more severe musculoskeletal disease. Several HLA-B alleles including B*44:02, B*44:03 and B*40:01 were found at significantly decreased frequency in the psoriatic arthritis cohort, suggesting they appear “protective” for the development of psoriatic arthritis [5]. It is important to emphasize that this study is based on a northern European population and that given the marked variation of these alleles across populations, these results may not apply to other populations.

**Figure 4:** A comparison of the frequencies of the principal HLA-B and HLA-C loci alleles positively associated with susceptibility to psoriatic arthritis depicted as Venn diagrams, emphasizing the difference between allele frequencies in healthy controls and psoriasis. It shows the psoriasis phenotype is not genetically homogeneous and that psoriatic arthritis (PsA) itself is genetically heterogeneous, with only a smaller subset genetically closely related to those with cutaneous psoriasis (PsC).
in different geographic regions across the globe, different associations will likely be present in these various populations.

A potential molecular basis for susceptibility

A potential molecular basis for susceptibility to psoriasis and psoriatic arthritis is suggested by comparing the architecture of the peptide-binding pockets and their peptide-binding preference for the various HLA allomorphs encoded by the alleles positively and negatively associated with psoriatic arthritis susceptibility. Figure 5 shows the single amino acid code for a portion of the amino acid residues of the B pocket of the HLA molecules and the principal patterns of peptide binding by HLA-B and HLA-C molecules associated with psoriatic arthritis susceptibility. The preferential peptide-binding specificity of the allomorphs for binding particular amino acid side chains at the second position of the peptide, P2, is shown. At positions 45, 67 and 74 in the HLA-B alpha chain forming critical parts of the B pocket, HLA-B*27:05:02, HLA-B*39:01:01 and B*38:01:01 are characterized by the same amino acid residues, containing negatively charged glutamic acid (at position 45) and aspartic acid (at position 74), and these allomorphs have been defined to preferentially bind peptides containing positively charged arginine or histidine at P2 [7, 8]. Specifically, the negatively charged amino acids in the HLA molecule pocket create a charge environment that non-covalently interacts with the opposite, positively charged amino acids at P2 of peptides via the formation of salt bridges, conferring high affinity binding to these allomorphs of peptides that have an arginine or histidine at this position. Conversely, the B*44 allomorphs associated with significantly decreased susceptibility to psoriatic arthritis are characterized with positively charged lysine at position 45, and this confers the preference to bind peptides with negatively charged amino acids at P2 of the peptide, glutamic and aspartic acids [5]. This pattern suggests that the inheritance of alleles encoding allomorphs with the ability to bind a self-peptide with arginine at P2 is a critical step in defining the predisposition to develop the molecular basis of the susceptibility to develop psoriatic arthritis, and that T cell repertoires developing in individuals on HLA-B allomorphs that preferentially bind peptides with negatively charged amino acid residues at P2 significantly decrease the likelihood of developing psoriatic arthritis.

The HLA-C*06:02 molecule differs slightly in features from the HLA-B molecule. It is also characterized by a negatively charged “B” pocket, in this case by an aspartic acid at position 9 in the alpha chain and by crystallography this residue forms a salt bridge with positively charged arginine at P2, the preferred anchoring side chain for binding peptides [9]. In this respect, there are intriguing analogies with the P2 binding properties of HLA-B*27:05:02, HLA-B*39:01:01 and B*38:01:01. However, HLA-C*06:02 differs from the previously described allomorphs in that it also anchors peptides by arginine, lysine or glutamine at P7. Future work will have to determine whether these intriguing analogies reflect binding of the similar peptides critical to the development of the autoimmune response underlying psoriatic arthritis. Similarly, HLA-B*08:01:01 molecules somewhat resemble HLA-B*27:05:02, HLA-B*39:01:01 and B*38:01:01 in having negatively charged residues at positions 45 and 74 and this is characterized by a preference for peptides containing lysine, methionine or arginine, but the preferential anchor site is P3. Here also, current knowledge is not sufficient to interpret precisely whether these clues suggest preferen-

<table>
<thead>
<tr>
<th>Amino Acid Position</th>
<th>Amino Acid Side Chain Anchoring Peptide</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Preferentially Bound by Allomorph</td>
</tr>
<tr>
<td>HLA-B</td>
<td></td>
</tr>
<tr>
<td>B*27:05:02</td>
<td>E</td>
</tr>
<tr>
<td>B*38:01:01</td>
<td>E</td>
</tr>
<tr>
<td>B*39:01:01</td>
<td>E</td>
</tr>
<tr>
<td>B*08:01:01</td>
<td>E</td>
</tr>
<tr>
<td>B*44:02:01</td>
<td>K</td>
</tr>
<tr>
<td>B*44:03:01</td>
<td>K</td>
</tr>
<tr>
<td>HLA-C</td>
<td></td>
</tr>
<tr>
<td>C*06:02:01</td>
<td>D</td>
</tr>
</tbody>
</table>

Figure 5: Illustrates the single amino acid code for a portion of the amino acid residues of the B pocket of the HLA molecules and the principal patterns of peptide binding by the HLA-B and HLA-C allomorphic molecules associated with significantly increased and decreased psoriatic arthritis susceptibility. The preferential peptide binding specificity of the allomorphs for binding particular amino acid side chains at the second position of the peptide P2 is shown. At positions 45, 67 and 74 in the HLA-B alpha chain forming critical parts of the B pocket, HLA-B*27:05:02, HLA-B*39:01:01 and B*38:01:01 have the same negatively charged amino acid residues, and these allomorphs have been defined to preferentially bind peptides containing positively charged arginine or histidine at P2 [7, 8]. Specifically, the negatively charged amino acids in the HLA molecule pocket create a charge environment that non-covalently interacts with the opposite, positively charged amino acids at P2 of peptides via the formation of salt bridges, conferring high affinity binding to these allomorphs of peptides that have an arginine or histidine at this position. Conversely, the B*44 allomorphs associated with significantly decreased susceptibility to psoriatic arthritis are characterized with positively charged lysine at position 45, conferring the preference to bind peptides with negatively charged amino acids at P2. The somewhat related properties of B*08:01:01 and C*06:02:01 are shown.
tial binding of a particular specific peptide. From the dominant nature of the association of each HLA allele with susceptibility, we infer that the binding property of the self-peptides by the allomorphs during thymic development of the repertoire results in a dominant recognition property of these particular repertoires, specified by each susceptibility allomorph of particular self-peptides.

The relation of psoriatic arthritis susceptibility genotypes to clinical subphenotypes.

Different genetic susceptibility genes imply different disease mechanisms and perhaps different clinical courses and therapeutic responses to particular biologies. Accordingly, we asked, is the phenotypic heterogeneity among patients with psoriatic arthritis related to their inheritance of different HLA alleles? The first clue of a genotype-phenotype relationship in psoriatic arthritis was the finding that the onset of arthritis developed closer to the appearance of psoriasis in the HLA-B*27:05:02 or B*39:01:01 subset than in the HLA-HLA-C*06:02 subset of psoriatic arthritis cases [5]. The mean number of years between the onset of psoriasis and diagnosis of psoriatic arthritis was 11.3 years among HLA-C*06:02 individuals and 3.8 years in those who were HLA-B*27:05:02 or B*39:01:01. This suggested the time interval between psoriasis and diagnosis of psoriatic arthritis is a genetically determined quantitative trait. The phenotype conferred by HLA-C*06:02 can accordingly be further defined as one of highly penetrant severe skin disease and lower penetrance and considerably delayed onset of musculoskeletal disease, while that conferred by HLA-B*27:05:02 or B*39:01:01 can define the more synchronous appearance of skin and musculoskeletal disease.

Since both the clinical phenotype and the HLA genotype were heterogeneous, one could ask whether a particular phenotype was associated with a specific HLA allele. Table 2 summarizes the reported univariate associations between certain clinical subphenotypes and psoriatic arthritis susceptibility alleles, and shows the differing genetic architecture underlying the development of clinical subphenotypes of psoriatic arthritis [10, 11]. One of the clinical features of psoriatic arthritis is the development of sacroiliitis, which more commonly is asymmetric, in contrast to that of ankylosing spondylitis, which is almost invariably bilateral as determined by conventional X-ray studies. In psoriatic arthritis, as in the instance of ankylosing spondylitis, symmetric sacroiliitis was significantly associated only with the presence of HLA-B*27:05:02 (OR 4.16, p <0.001), whereas the presence of C*06:02 was borderline negatively associated with this form of sacroiliitis. In striking contrast, asymmetric sacroiliitis was significantly increased in frequency only among those who inherited HLA-B*08:01, with no positive association with HLA-B*27:05:02 or C*06:02.

Enthesitis, determined by physical examination, was significantly associated with HLA-B*27:05:02, whereas dactylitis was significantly positively associated with either HLA-B*27:05:02 or B*08:01, and nail disease was only positively associated with HLA-B*08:01. Again, the presence of C*06:02 was negatively associated with nail disease and dactylitis [12]. The implication of this relation between genotype and subphenotype is that a given subphenotype, such as enthesitis, reflects a specific autoimmune attack on the molecules comprising the enthesis by T cells that were selected on HLA-B*27:05:02 molecules in the thymus, and among this repertoire of T cells might well have been some that were positively selected on peptides from self-molecules identical to those found in the enthesis. In this sense, the intriguing difference between symmetric and asymmetric sacroiliitis in terms of a completely different HLA association accounts for the overall difference in the pattern of axial involvement between psoriatic arthritis and ankylosing spondylitis, and suggests that although at a given specific site the involvement appears radiographically equivalent, it is the result of a different autoimmune response, and differs in the molecules targeted by each immune response. A further implication of this concept would be that the spine involvement in an HLA-B*27:05:02 psoriatic arthritis patient would be more analogous to that of ankylosing spondylitis in terms of natural history and therapeutic response than that of a HLA-B*08:01 psoriatic arthritis patient. Since the CASPAR classification criteria to ascertain the diagnosis of psoriatic arthritis relies on the presence of clinical subphenotypes such as sacroiliitis, enthesitis, dactylitis and nail disease that are dependent on the individual’s HLA type (see table 2), the determination of the development of psoriatic arthritis among those with psoriasis, who are predominantly HLA-C*06:02, might by falsely underestimated because this population is less likely to exhibit these clinical subphenotypes [11]. It is likely that the HLA genetics will determine the clinical response of psoriatic arthritis to biologic agents and other newer therapeutic agents exhibiting heightened specificity for a particular inflammatory pathway. This has clearly been found to be the case in psoriasis where HLA-C*06:02-positive patients had a significantly superior response to the interleukin-12–interleukin-23 blocking biologic ustekinumab, whereas HLA-C*06:02-negative patients were significantly more likely to respond to the tumor necrosis factor inhibitor adalimumab, than to ustekinumab [13, 14].

Table 2: Differing genetic architecture underlying development of clinical subtypes of psoriatic arthritis.

<table>
<thead>
<tr>
<th>.</th>
<th>Asymmetric sacroiliitis vs no sacroiliitis</th>
<th>Symmetric sacroiliitis vs no sacroiliitis</th>
<th>Enthesitis</th>
<th>Dactylitis</th>
<th>Nail disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>p-value</td>
<td>OR</td>
<td>p-value</td>
<td>OR</td>
</tr>
<tr>
<td>HLA-B*08:01:0</td>
<td>1.97</td>
<td>0.008</td>
<td>0.49</td>
<td>0.07</td>
<td>0.81</td>
</tr>
<tr>
<td>HLA-B*27:05:02</td>
<td>1.24</td>
<td>0.57</td>
<td>4.16</td>
<td>&lt;0.001</td>
<td>3.65</td>
</tr>
<tr>
<td>HLA-B*38:01:01</td>
<td>2.87</td>
<td>0.065</td>
<td>1.92</td>
<td>0.42</td>
<td>1.25</td>
</tr>
<tr>
<td>HLA-B*39:01:0</td>
<td>0.4</td>
<td>0.22</td>
<td>1.06</td>
<td>0.93</td>
<td>0.97</td>
</tr>
<tr>
<td>HLA-C*06:02</td>
<td>0.54</td>
<td>0.36</td>
<td>0.47</td>
<td>0.053</td>
<td>1.09</td>
</tr>
</tbody>
</table>

OR = odds ratio
Genotypic interactions among susceptibility haplotypes determine psoriatic arthritis severity

Since we inherit one haploid chromosome from each of our parents, the question arises of how to determine the contribution of both maternal and paternal alleles on the resultant phenotype and severity of clinical disease. One initial simplified approach to answer this question was to use propensity analysis to assess the positive and negative contribution of risk alleles on both chromosomes to the resulting severity of the psoriatic arthritis phenotype. A disease severity score was developed based on the presence of enthesis, sacroiliitis, dactylitis, joint deformity, joint fusion, erosions or osteolysis. The patients were then ranked into severity tertiles, enabling address of the question: what combination of HLA haplotypes or alleles resulted in the greatest probability of being in the highest severity tertile? An HLA weighted risk score was developed that gave 1 point for each instance of the presence of the HLA-B*08:01-C*07:01 ancestral haplotype, the HLA-B*27:05:02-C*02:02 ancestral haplotype and the HLA-B*37:01-C*06:02 ancestral haplotype, which were separately associated with one or more psoriatic arthritis subphenotypes, 0 for the presence of the HLA-B*57:01-C*06:02 ancestral haplotype, which was neither positively or negatively associated with a phenotype, and −1 for the presence of B*44:02:01 or C*07:02 alleles, which were negatively associated with the features in the disease severity score. Thus, an individual could have an HLA allele risk score ranging from −2 to +2 and a person who was homozygous for B*27:05:02-C*02:02 receives a score of 2. The result for all the patients in the cohort is illustrated in figure 6 and shows the contribution of six positive or negative risk alleles/haplotypes on both chromosomes to the probability of having the greatest psoriatic arthritis severity, which is best explained by this additive model in which the positive and negative risk alleles independently contribute to the composite phenotype of more severe disease [10]. Of course, more detailed analyses using larger cohorts with additional alleles are required to better delineate the relationship between genotype and phenotype.

This suggests that in an individual with psoriatic arthritis, each T cell repertoire resulting from selection on a particular HLA molecule and associated with a psoriatic arthritis subphenotype functions in parallel in the autoimmune response to different self-molecules. However, the repertoires do not function independently of one another. HLA alleles such as B*44:02:01 that are associated with a decrease risk of developing psoriatic arthritis if present in an individual with a risk allele such as B*27:05:02, diminish the effect of the risk allele on conferring a severe disease phenotype. Conversely, other alleles such as B*08:01, enhance the effect of a risk allele. Accordingly, we conceptualize psoriatic arthritis as a complex autoimmune-mediated disease with a variety of subphenotypes that are under the control of different HLA alleles, reflecting the presence immune responses directed to different target molecules, but acting in concert to result in a spectrum of severity.

Conclusion

Pondering the answer to the question, “how did my psoriatic arthritis come to be?” takes us on an exploration of the deeper meaning of the association of a disease with a particular HLA allele. The apparent seamless function of the adaptive immune response belies its astonishing genetic intricacy, which itself is an evolutionary response to pathogen challenge. The allelic complexity of the HLA system results in the near uniqueness of each individual’s immune system because the T cells are selected on self-peptides contained in self-HLA molecules. However, the impressive survival advantage of the adaptive immune system comes at the cost of autoimmunity and autoimmune disease because of the self-selected character of the adaptive immune system’s T cell repertoires. In some circumstances this results in the persistent and expanding self-directed immune response that underlies the particular clinical phenotype of the patient’s disease, and represents a therapeutic challenge to down-modulate. One can anticipate that in the next decade the knowledge hinted at in this simple guide will become much more clearly etched and therapeutically relevant.

Disclosure statement

No financial support and no other potential conflict of interest relevant to this article was reported.

References

3. Okada Y, Han B, Tosi LC, Stuart PE, Ellinghaus E, Tejani T, et al. Fine mapping major histocompatibility complex associations in psoriasis and...


